keyword
MENU ▼
Read by QxMD icon Read
search

Virus C and liver transplantation

keyword
https://www.readbyqxmd.com/read/28092420/immune-modulation-by-the-hepatitis-c-virus-core-protein
#1
Cecilia Fernández-Ponce, Juan Pedro Muñoz-Miranda, Mikel M Arbulo-Echevarria, Rocío Litrán, Enrique Aguado, Francisco García-Cozar
Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral persistence. Several HCV viral proteins have been described as immune modulators. In this review, we will focus on the effect of HCV nucleocapsid core protein in the function of immune cells and its correlation with the findings observed in HCV chronically infected patients...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28088461/changes-in-the-prevalence-of-hepatitis-c-virus-infection-non-alcoholic-steatohepatitis-and-alcoholic-liver-disease-among-patients-with-cirrhosis-or-liver-failure-on-the-waitlist-for-liver-transplantation
#2
David Goldberg, Ivo C Ditah, Kia Saeian, Mona Lalehzari, Andrew Aronsohn, Emmanuel C Gorospe, Michael Charlton
BACKGROUND & AIMS: Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV), infection, there has been an increase in the incidence of non-alcoholic fatty liver disease (NAFLD). Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States...
January 11, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28070200/the-risk-of-hepatocellular-carcinoma-after-directly-acting-antivirals-for-hepatitis-c-virus-treatment-in-liver-transplanted-patients-is-it-real
#3
Alessio Strazzulla, Rosa Maria Rita Iemmolo, Ennio Carbone, Maria Concetta Postorino, Maria Mazzitelli, Mario De Santis, Fabrizio Di Benedetto, Costanza Maria Cristiani, Chiara Costa, Vincenzo Pisani, Carlo Torti
INTRODUCTION: Since directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) were introduced, conflicting data emerged about the risk of hepatocellular carcinoma (HCC) after interferon (IFN)-free treatments. We present a case of recurrent, extra-hepatic HCC in a liver-transplanted patient soon after successful treatment with DAAs, along with a short review of literature. CASE PRESENTATION: In 2010, a 53-year old man, affected by chronic HCV (genotype 1) infection and decompensated cirrhosis, underwent liver resection for HCC and subsequently received orthotopic liver transplantation...
November 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/28070175/a-special-meeting-review-edition-advances-in-the-treatment-of-hepatitis-c-virus-infection-from-the-2016-easl-meeting-the-annual-meeting-of-the-european-association-for-the-study-of-the-liver-%C3%A2-april-13-17-2016-%C3%A2-barcelona-spainspecial-reporting-on-%C3%A2-six-weeks
#4
https://www.readbyqxmd.com/read/28070117/re-transplantation-higher-creatinine-levels-in-hepatitis-c-virus-patients-and-donor-age-are-predictors-of-mortality-in-long-term-analysis-of-late-acute-rejection-in-liver-transplantation
#5
Lucas Souto Nacif, Rafael Soares Pinheiro, Rafael Antônio de Arruda Pécora, Ryan Yukimatsu Tanigawa, Vinicius Rocha-Santos, Wellington Andraus, Venancio Avancini Ferreira Alves, Luiz Carneiro D'Albuquerque
BACKGROUND Late acute rejection (LAR) differs in its clinical and histological presentation and management from early acute rejection. This clinical entity is not completely understood; thus, we aimed to identify significant prognostic factors that can influence post-transplant survival in LAR patients. The purpose of this study was to evaluate the incidence and post-transplant survival of patients from a single center with a focus on late acute rejection. MATERIAL AND METHODS From January 2002 to June 2013, all liver biopsies from patients with rejection were scored using the Banff criteria...
January 10, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28060446/successful-treatment-of-donor-derived-hepatitis-c-viral-infection-in-three-transplant-recipients-from-a-donor-at-increased-risk-for-bloodborne-pathogens
#6
Ashesh P Shah, Andrew Cameron, Pooja Singh, Adam M Frank, Jonathan M Fenkel
We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)-negative donor to 3 HCV-negative recipients - 2 renal transplants and 1 liver. Both renal recipients underwent standard deceased-donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. The donor was a 39-year-old woman with a terminal serum creatinine of 0.7 mg/dL. She was high risk for bloodborne pathogens, based upon a history of sexual contact with an HCV-infected male partner...
January 6, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28060241/disease-reversibility-in-patients-with-posthepatitis-c-cirrhosis-is-the-point-of-no-return-the-same-before-and-after-liver-transplantation-a-review
#7
Carmen Vinaixa, Simone I Strasser, Marina Berenguer
Liver fibrosis can regress in patients with chronic hepatitis in whom the underlying cause of liver damage is adequately treated. Studies documenting this benefit have been mostly performed in the setting of viral hepatitis, particularly hepatitis C virus (HCV), where sustained viral response (SVR) has been unequivocally shown to result in histological and clinical improvement. With the advent of the new interferon (IFN)-free regimens, highly effective and safe even in those historically considered "difficult to treat and cure patients", additional benefits have been documented in patients treated at advanced stages of disease, including improvement in liver function with hepatic "re-compensation", reduction of portal hypertension, and eventually avoidance of liver transplantation (LT)...
January 6, 2017: Transplantation
https://www.readbyqxmd.com/read/28058221/quality-of-life-10-years-after-liver-transplantation-the-impact-of-graft-histology
#8
Vincent Karam, Mylène Sebagh, Kinan Rifai, Funda Yilmaz, Prashant Bhangui, Colette Danet, Faouzi Saliba, Didier Samuel, Denis Castaing, René Adam, Cyrille Feray
AIM: To evaluate the relationship between the state of transplanted liver graft and the recipient quality of life (QOL) of histologically proven lesions in a 10-year post liver transplantation (LT) cohort of patients. METHODS: Seventy-two recipients with a functional first graft at 10 years post-LT underwent liver biopsy and completed a QOL questionnaire. Logistic regression analysis was used to explore associations between histological, clinical and QOL criteria...
December 24, 2016: World Journal of Transplantation
https://www.readbyqxmd.com/read/28052626/therapies-in-non-alcoholic-steatohepatitis-nash
#9
REVIEW
Abdul M Oseini, Arun J Sanyal
The hallmark of non-alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non-alcoholic fatty liver, NAFL) or accompanied by evidence of inflammation and cell injury with or without fibrosis (non-alcoholic steatohepatitis, NASH). NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma. Since NASH is estimated to overtake hepatitis C virus infection as the leading cause of liver transplantation in the US in the coming decade, and there are no current FDA-approved therapies for this disease, the need to find appropriate therapeutic targets is now more urgent than ever before...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28052618/the-future-of-liver-transplantation-for-viral-hepatitis
#10
REVIEW
François Durand, Claire Francoz
In hepatitis C virus (HCV)-infected patients, transplantation can be justified by decompensated cirrhosis, hepatocellular carcinoma (HCC) or both. During the last decade, HCV infection accounted for about 30% of the indications for transplantation in Europe and North America. Direct antiviral agents (DAAs) are highly effective at curing HCV, even in patients with end-stage cirrhosis. In the future, the incidence of HCV-related decompensated cirrhosis will continue to decrease. The incidence of HCC will also decrease, but a large cohort of patients with cirrhosis will still be at risk of developing HCC even after HCV has been cured...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28052604/optn-srtr-2015-annual-data-report-liver
#11
W R Kim, J R Lake, J M Smith, M A Skeans, D P Schladt, E B Edwards, A M Harper, J L Wainright, J J Snyder, A K Israni, B L Kasiske
Several notable developments in adult liver transplantation in the US occurred in 2015. The year saw the largest number of liver transplants to date, leading to reductions in median waiting time, in waitlist mortality for all model for end-stage liver disease categories, and in the number of candidates on the waiting list at the end of the year. Numbers of additions to the waiting list and of liver transplants performed in patients with hepatitis C virus infection decreased for the first time in recent years...
January 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28051797/%C3%A2-sofosbuvir-and-daclatasvir-in-mono-and-hiv-coinfected-patients-with-recurrent-hepatitis-c-after-liver-transplant
#12
Lluís Castells, Jordi Llaneras, Isabel Campos-Varela, Itxarone Bilbao, Manel Crespo, Oscar Len, Francisco Rodríguez-Frías, Ramon Charco, Teresa Salcedo, Juan Ignacio Esteban, Rafael Esteban-Mur
:  Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-HCV coinfected patients. MATERIAL AND METHODS: We retrospectively evaluated 22 consecutive adult LT recipients (16 monoinfected and 6 coinfected with HIV) who received a 24-week course of sofosbuvir plus daclatasvir treatment under an international compassionate access program...
January 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28045877/the-path-to-cancer-and-back-immune-modulation-during-hepatitis-c-virus-infection-progression-to-fibrosis-and-cancer-and-unexpected-roles-of-new-antivirals
#13
Jose D Debes, Robert J de Knegt, Andre Boonstra
Hepatitis C virus (HCV) infection affects over 130 million individuals worldwide, and it is the number 1 reason for liver transplantation in the United States. HCV infection progresses in a slow chronic fashion eliciting a strong but ineffective immune response, mainly characterized by NK cell dysfunction and T cell exhaustion. The chronic hepatic inflammation leads to liver fibrosis, cirrhosis and cancer in a significant number of patients. In recent years, groundbreaking research has led to the discovery of new HCV-specific direct acting antivirals (DAAs), which have an unprecedented efficacy to clear the virus, and establish a sustained virological response...
December 30, 2016: Transplantation
https://www.readbyqxmd.com/read/28039929/epstein-barr-virus-dna-monitoring-in-serum-and-whole-blood-in-pediatric-liver-transplant-recipients-who-do-or-do-not-discontinue-immunosuppressive-therapy
#14
C Kullberg-Lindh, R Saalman, M Olausson, G Herlenius, M Lindh
The rate of PTLD can be reduced by weaned IS guided by monitoring of EBV DNA. In this single-center retrospective case series study, we analyzed how reduction in IS influenced EBV DNA levels in whole blood and serum in 30 children during the first year after liver transplantation, and how these levels were related to symptoms putatively due to EBV. Primary and reactivated EBV infection was seen in 18 (60%) and eight patients (27%), respectively. Thirteen patients (42%) developed chronic high load the first year post-transplant...
December 31, 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/28024124/developing-therapies-to-treat-hepatitis-c-infection-in-post-liver-transplant-recipients
#15
Thomas R McCarty, Joseph K Lim
Currently, hepatitis C virus (HCV) infection remains the most common indication for liver transplant in the United States (US) with almost universal HCV recurrence in the post-liver transplant setting. Previous interferon (IFN)-related efficacy and tolerability concerns about worsening liver function have limited treatment options for many patients with HCV-associated decompensated liver disease and post-liver transplant recipients. However, the last decade has seen a seen a radical shift in the management of HCV with multiple direct-acting antiviral (DAA) treatments that provide more effective, all-oral, IFN-free alternatives...
December 26, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28013117/hepatocellular-carcinoma-is-the-most-common-indication-for-liver-transplantation-and-placement-on-the-waitlist-in-the-united-states
#16
Ju Dong Yang, Joseph J Larson, Kymberly D Watt, Alina M Allen, Russell H Wiesner, Gregory J Gores, Lewis R Roberts, Julie A Heimbach, Michael D Leise
BACKGROUND & AIMS: Management strategies for patients with hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC) have changed, along with liver allocation policies based on model for end-stage liver disease (MELD) score. We investigated etiologic-specific trends in liver transplantation in the United States (US) during different time periods. METHODS: We performed a retrospective study, using the United Network for Organ Sharing/ Organ Procurement and Transplantation Network registry data to identify all adult patients registered for liver transplantation in the US from January 1, 2004 through December 31, 2015...
December 21, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28012259/reduction-in-liver-transplant-wait-listing-in-the-era-of-direct-acting-antiviral-therapy
#17
Jennifer A Flemming, W Ray Kim, Carol L Brosgart, Norah A Terrault
: Direct-acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic function. We analyzed trends in liver transplant (LT) wait-listing (WL) to explore potential impact of effective medical therapy on WL registration. This is a cohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015. A total of 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) were identified...
November 5, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28002876/outcomes-of-treatment-with-daclatasvir-and-asunaprevir-for-recurrent-hepatitis-c-after-liver-transplantation
#18
Masaki Honda, Yasuhiko Sugawara, Takehisa Watanabe, Masakuni Tateyama, Motohiko Tanaka, Koushi Uchida, Seiichi Kawabata, Daiki Yoshii, Kouhei Miura, Kaori Isono, Shintaro Hayashida, Yuki Ohya, Hidekazu Yamamoto, Yutaka Sasaki, Yukihiro Inomata
AIM: The development of direct - acting oral agents has dramatically changed the treatment strategy of hepatitis C virus (HCV) infection. Here we aimed to reveal the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) for recurrent HCV genotype 1 infection after liver transplantation (LT). METHODS: A retrospective study was conducted on 9 patients [5 men; 4 had failed peg-interferon/ribavirin, 2 had failed simeprevir/peg-interferon/ribavirin, 1 had the resistance-associated variant (RAV) Y93H in the NS5A region, 1 underwent maintenance dialysis ] who underwent a 24 -week DCV/ASV treatment regimen for recurrent HCV genotype 1 infection...
December 21, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27996360/liver-transplantation-for-hepatocellular-carcinoma-in-young-adults-a-united-network-for-organ-sharing-study
#19
Stefanie M Thomas, Diana Moke, Rocio Lopez, Rabi Hanna, Mohammad Nasser Kabbany, Naim Alkhouri
PURPOSE: Orthotopic liver transplantation (OLT) is curative for hepatocellular carcinoma (HCC). HCC is typically a disease of older adults (OAs); therefore, characteristics and outcomes of OLT for young adults (YAs) (ages 18-40) are not described. The objective of this study was to assess the characteristics and outcomes of YAs with HCC receiving OLT and compare these to OAs (ages >40 years). METHODS: YAs with HCC who had OLT from the United Network for Organ Sharing (UNOS) database were included in this study...
December 20, 2016: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/27995739/survival-in-patients-with-child-pugh-class-c-cirrhosis-analysis-of-the-liver-transplant-registry-in-japan
#20
Takuya Genda, Takafumi Ichida, Shotaro Sakisaka, Eiji Tanaka, Satoshi Mochida, Yoshiyuki Ueno, Ayano Inui, Hiroto Egawa, Koji Umeshita, Hiroyuki Furukawa, Seiji Kawasaki, Yukihiro Inomata
AIM: To clarify the survival and prognostic factors in patients with Child-Turcotte-Pugh class C (CTP-C) cirrhosis. METHODS: From all candidates for deceased donor liver transplantation in Japan between 2007 and 2015, 1014 adult patients with CTP-C cirrhosis were retrospectively enrolled in this study. Hazard ratio (HR) of factors associated with mortality was estimated by Cox proportional hazard model. The survival probabilities were evaluated by Kaplan-Meier analysis and the log-rank test...
December 20, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
keyword
keyword
112674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"